Latest news with #RamPrasadSahu
&w=3840&q=100)
Business Standard
2 days ago
- Automotive
- Business Standard
Bajaj Auto's premium segment revival needs more than just a kickstart
KTM's tune-up will decide whether automaker can regain its premium balance Ram Prasad Sahu Mumbai Listen to This Article Bajaj Auto — the country's most valuable two-wheeler (2W) company by market capitalisation — met Street expectations in the January–March quarter (Q4) of 2024–25 (FY25) but still ended Friday as the worst performer on the Nifty 50, slipping 3.1 per cent. While operating margins held steady during the quarter, the market is uneasy about the company's shrinking share in the domestic motorcycle segment. Any further upside for the stock will hinge on how soon KTM turns the corner. Analysts believe gains in electric two-wheelers (e2Ws) and exports are already priced in. Q4 sales came in slightly ahead of expectations, rising
&w=3840&q=100)
Business Standard
27-05-2025
- Automotive
- Business Standard
Demand and margin gains to power M&CV company Ashok Leyland's stock
Ashok Leyland's strong Q4 led by 5% volume growth and margin gains; focus on exports, non-CV business and cost control to support performance in FY26 Ram Prasad Sahu New Delhi The country's second-largest medium and heavy commercial vehicle (M&HCV) company, Ashok Leyland, posted a healthy operational performance in the March (Q4FY25) quarter. Higher volumes and a slight improvement in average selling prices helped drive gains on the top line. The company expects growth in some of the key segments within the commercial vehicle market in FY26. This, coupled with an increase in the non-CV share of revenue and its net cash position, will help the company maintain a steady revenue trajectory while exploring new growth opportunities. While the company has outperformed the Nifty Auto index over
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
Weak guidance, higher costs to weigh on Sun Pharma's FY26 outlook
Sun Pharma's FY26 revenue guidance disappoints Street expectations as higher specialty product costs in the US prompt brokerages to cut earnings estimates Ram Prasad Sahu Listen to This Article Despite a healthy performance in the fourth quarter of financial year 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with. This coupled with higher expenses related to the launch of specialty products in the US market has prompted brokerages to cut their earnings estimates for FY26 by 4-8 per cent. The stock was the only loser in the Sensex, shedding 2 per cent,
&w=3840&q=100)
Business Standard
19-05-2025
- Business
- Business Standard
Strong growth seen for Divi's Laboratories, but upside capped by valuations
Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range Ram Prasad Sahu Listen to This Article The stock of contract development and manufacturing organisation (CDMO) Divi's Laboratories was among the top gainers in the BSE 100 index on Monday. It rose 4.81 per cent as fourth-quarter revenues beat estimates across key segments, while margins hit multi-quarter highs. The management has guided for double-digit growth for 2025–26 (FY26), which, coupled with stronger momentum from China+1 and the commercialisation of the blood sugar control drug glucagon-like peptide-1 (GLP-1), will act as key triggers. Brokerages, however, believe upsides are limited as valuations have turned expensive. Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although
&w=3840&q=100)
Business Standard
18-05-2025
- Business
- Business Standard
Paint major Berger's palette finds contrast in a washed-out quarter
Few stay in frame as soft sales and rising competition blur the outlook canvas Ram Prasad Sahu Mumbai Listen to This Article Listed paint majors posted another lacklustre showing in the January–March quarter (Q4) of 2024–25 (FY25), with average revenue growth under 3 per cent. Sales were weighed down by Asian Paints — the market leader and the only major to report a year-on-year (Y-o-Y) decline. Excluding Asian Paints, the rest of the sector managed 5 per cent growth. Top paint stocks have consistently lagged behind benchmark indices and sectoral peers (BSE FMCG and BSE Consumer Discretionary) across time frames from three months to two years. Brokerages remain wary, citing weak demand and intensifying competition. Despite these headwinds, paint stocks are still
